SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Krensavage Asset Management, LLC

CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582

Reported Value
$342M
Q4 2020
Positions
12
Filings on Record
32
2019–present window
Filed
Feb 17, 2021
original filing

Summary

Krensavage Asset Management, LLC reported $342M in U.S.-listed holdings across 12 positions for Q4 2020.

Its largest position, ALXN, represents 16.6% of the portfolio.

Compared with Q3 2020, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+4.0%
vs prior filed quarter
Top-10 Concentration
+99.2%
share of reported value
Largest Position
+16.6%
Alexion Pharmaceuticals

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $370MQ1 ’19Q2 ’19: $308MQ3 ’19: $260MQ4 ’19: $293MQ1 ’20: $311MQ1 ’20Q2 ’20: $368MQ3 ’20: $314MQ4 ’20: $342MQ1 ’21: $289MQ1 ’21Q2 ’21: $295MQ3 ’21: $319MQ4 ’21: $288MQ1 ’22: $290MQ1 ’22Q2 ’22: $302MQ3 ’22: $314MQ4 ’22: $324MQ1 ’23: $329MQ1 ’23Q2 ’23: $316MQ3 ’23: $272MQ4 ’23: $282MQ1 ’24: $226MQ1 ’24Q2 ’24: $218MQ3 ’24: $178MQ4 ’24: $169MQ1 ’25: $181MQ1 ’25Q2 ’25: $189MQ3 ’25: $235MQ4 ’25: $283MQ1 ’26: $256MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 88.0%Other: 12.0%
  • Common Stock · 88.0% · $301M
  • Other · 12.0% · $41M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NEXTCURE INCNEW+30.3K30.3K+$330,000$330,000
UTHRUNITED THERAPEUTICS CORPTRIMMED−103.7K322.5K+$6M$49M
MCKMCKESSON CORPTRIMMED−19.0K167.0K+$1M$29M
ALXNALEXION PHARMACEUTICALS INCTRIMMED−32.3K364.3K+$12M$57M
ANABANAPTYSBIO INCTRIMMED−8.4K110.4K+$622,000$2M
ENTAENANTA PHARMACEUTICALS INCHELD+33.5K858.8K−$2M$36M
ALKSALKERMES PLCHELD+48.3K1.62M+$6M$32M
TARO PHARMACEUTICAL INDUSHELD+16.3K553.6K+$11M$41M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ALXNALEXION PHARMACEUTICALS INChistory →COM16.62%$57M364.3K
2UTHRUNITED THERAPEUTICS CORPhistory →COM14.30%$49M322.5K
3TARO PHARMACEUTICAL INDUSCOM11.87%$41M553.6K
4REGNREGENERON PHARMACEUTICALShistory →COM11.60%$40M82.2K
5ENTAENANTA PHARMACEUTICALS INChistory →COM10.56%$36M858.8K
6BIIBBIOGEN INChistory →COM9.87%$34M138.0K
7ALKSALKERMES PLChistory →COM9.44%$32M1.62M
8MCKMCKESSON CORPhistory →COM8.48%$29M167.0K
9SURGALIGN HOLDINGS INCCOM4.11%$14M6.42M
10INVACARE CORPCOM2.36%$8M904.5K
11ANABANAPTYSBIO INCCOM0.69%$2M110.4K
12NEXTCURE INCCOM0.10%$330,00030.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$256M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$283M18Feb 18, 202613F-HRchanges · EDGAR ↗
Q3 2025$235M17Nov 17, 202513F-HRchanges · EDGAR ↗
Q2 2025$189M15Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$181M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$169M12Feb 18, 2025RESTATEMENTchanges · EDGAR ↗
Q3 2024$178M13Nov 15, 202413F-HRchanges · EDGAR ↗
Q2 2024$218M13Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$226M12May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$282M12Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$272M12Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$316M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$329M12May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$324M12Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$314M14Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M14Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$290M13May 17, 202213F-HRchanges · EDGAR ↗
Q4 2021$288M10Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$319M13Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$295M13Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$289M12May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$342M12Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$314M11Dec 8, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$368M11Aug 20, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$311M13May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$293M12Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$260M10Nov 15, 201913F-HRchanges · EDGAR ↗
Q2 2019$308M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M12May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.